Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

Neurology News Network. for the week ending March 29, 2025. [WATCH TIME: 3 minutes]

HEALEY-ALS Platform Trial Amended, WVE-N531 Improves Muscle Growth in DMD, Diazoxide Choline Approved for Prader-Willi Syndrome

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 28, 2025. 

NeurologyLive® Friday 5 — March 28, 2025

AHN Neuroscience Institute is using advanced, minimally invasive spinal surgery techniques to treat complex spine conditions, offering faster recovery, smaller incisions, and improved patient outcomes.

Maximal Results With Minimal Invasion: Enhancing AHN Patient Outcomes With Advanced Spine Surgery Techniques

AHN Neuroscience Institute is the first in western Pennsylvania to offer the FDA-approved Vivistim device, combining vagus nerve stimulation with traditional rehab to improve stroke recovery.

A Revolutionary Treatment for Stroke: How a Vagus Nerve Stimulation Implant is Giving Patients Renewed Hope 

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

In this third episode, experts delve into the evolving role of optic neuritis and the central vein sign in refining multiple sclerosis diagnosis, highlighting their significance in distinguishing MS from other conditions and ensuring accurate patient care. [WATCH TIME: 3 minutes]

Educating the Clinical Community on Changes to MS Diagnostic Criteria

Panelists explore the impact of including optic nerve involvement in the diagnostic criteria for multiple sclerosis, highlighting how this revision leads to more definitive diagnoses and earlier initiation of treatment for patients at high risk. [WATCH TIME: 2 minutes]

Impact of Optic Nerve Inclusion on Early MS Diagnosis and Treatment

In this panel discussion, clinicians dive into the crucial role of neuro-ophthalmologists in diagnosing and managing visual symptoms in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

Role of Neuro-Ophthalmologists in Care Paradigm of Multiple Sclerosis

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Updates in the Management of Relapsing Multiple Sclerosis

Fred Lublin, MD; Patricia K. Coyle, MD; Mark Freedman, MD; and Scott D. Newsome, DO, discuss a number of topics pertaining to the diagnosis of multiple sclerosis, including a focus on fatigue and its impact on quality of life.

2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis 

Use of MRI in Diagnosing Multiple Sclerosis 

Misdiagnosis of Multiple Sclerosis

Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

Challenges in Optimally Treating Multiple Sclerosis

 QoL Issues in the Management of Multiple Sclerosis

Multiple Sclerosis Fatigue

TRIUMPHANT-MS Trial: Fatigue in MS

OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

Strategies for Choosing Initial Therapy in MS

Anti-CD20 Monoclonal Antibodies for Treatment of RMS

Cladribine for Treatment of RMS

S1P Receptor Modulators for Treatment of RMS

Fumarates for Treatment of RMS

The Future of Managing Multiple Sclerosis

Peer Exchange

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Fumarates for Treatment of RMS

EP: 1.2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis

EP: 2.Use of MRI in Diagnosing Multiple Sclerosis

EP: 3.Misdiagnosis of Multiple Sclerosis

EP: 4.Cerebrospinal Fluid in Diagnosing Multiple Sclerosis

EP: 5.Challenges in Optimally Treating Multiple Sclerosis

EP: 6. QoL Issues in the Management of Multiple Sclerosis

EP: 7.Multiple Sclerosis Fatigue

EP: 8.TRIUMPHANT-MS Trial: Fatigue in MS

EP: 9.OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue

EP: 10.Strategies for Choosing Initial Therapy in MS

EP: 11.Anti-CD20 Monoclonal Antibodies for Treatment of RMS

EP: 12.Cladribine for Treatment of RMS

EP: 13.S1P Receptor Modulators for Treatment of RMS

EP: 14.Fumarates for Treatment of RMS

EP: 15.The Future of Managing Multiple Sclerosis